Environmental Performance

We present the following environmental performance information related to our operations:

Unless otherwise noted, this website covers data from 2001 through 2006.

We also breakdown the following 2005 environmental performance data by region:

Energy use
Water use
Greenhouse gas emissions
Nonhazardous waste generation
Hazardous waste generation
Wastewater releases of chemical oxygen demand, total suspended solids, and nitrates

Management Approach

Bristol-Myers Squibb's management approach to our environmental performance is discussed below.

Policy

The Bristol-Myers Squibb Pledge is the overarching policy regarding our company's sustainability performance. In it, "we pledge—to our patients and customers, to our employees and partners, to our shareholders and neighbors, and to the world we serve—to act on our belief that the priceless ingredient of every product is the honor and integrity of its maker." The Pledge specifically addresses our commitments to key stakeholders: employees, suppliers and partners, shareholders, and the communities where we live and work, the countries where we do business, and the world we serve.

In addition, our EHS Policy reflects the promise of our Pledge and mission.

Goals and Performance

In support of our policy, we established Sustainability 2010 Goals. These goals, by design, support our company’s business objectives and should result in environmental, social, and financial benefits to the company, our stakeholders, and the world around us.

Organizational Responsibility

The most senior position with operational responsibility for environmental aspects is the Vice President, Environment, Health and Safety and Corporate Product Quality, who reports to the Vice President, Deputy General Council and Chief Compliance Officer. The Chief Compliance Officer reports to the interim General Counsel and Corporate Secretary, who reports to the CEO.

Division presidents are held accountable for implementation of the EHS Policy within their divisions. The company has a Corporate EHS Steering Committee and European EHS Working Committee.

Training and Awareness

Employee awareness and training are at the core of Bristol-Myers Squibb's goal to become a leader in EHS management. Bristol-Myers Squibb provides guidelines for training both new and experienced employees. In addition, facility environmental coordinators and other full-time EHS professionals must complete, at company expense, at least 40 hours of annual EHS training related to their job assignments. Other company education initiatives include corporate and divisional intranet web sites; employee publications; functional and cross-functional group meetings; management awareness training; and topic-specific training and manuals.

Monitoring and Follow-up

A comprehensive, rigorous EHS evaluation process is key to ensuring that we maintain and continuously improve a compliant, safe, and healthy workplace. EHS evaluations are designed to verify consistency of business operations with internal and external technical EHS and transportation requirements and to assess the adequacy of management systems in place at the company’s operations to support on-going compliance. Corporate, business unit, and facility management use the results of the evaluations to maintain and continuously improve EHS performance companywide.

All manufacturing and research and development facilities, plus distribution and office locations, are evaluated. The frequency, which typically ranges from 18 to 60 months, depends on EHS and business risk factors, and on the maturity of the facility EHS management systems. During 2005, EHS evaluations were conducted at 31 facilities. Action plans are being actively monitored.

Under guidelines relating to contract manufacturers and suppliers, divisions conduct EHS evaluations of the facilities and operating practices of contract manufacturers and selected suppliers. The guidelines address topics such as: chemical storage and handling practices; waste storage, handling, and disposal practices and sites; permits; emergency preparedness and response; employee exposure; regulatory compliance history; and financial position.

Several Bristol-Myers Squibb facilities are certified to ISO 14001.

Additional Information

Information on the company's key environmental successes and challenges are included in discussions of our Sustainability 2010 Goals, key sustainability indicators and throughout the Environmental Performance section of this website.

Process for Data Collection

We collect environmental data from our manufacturing, research and development, and distribution facilities throughout the world.

U.S. SARA 313 Releases

Bristol-Myers Squibb facilities in the United States report annually on releases of toxic chemicals to the air, water, and land. The toxic release inventory (TRI) is required under Section 313 of the Superfund Amendments and Reauthorization Act (SARA). Releases are defined broadly under SARA Section 313 to include the off-site transfer of chemicals in addition to air emissions and wastewater discharges.

This website contains links to the U.S. government's TRI database for all facilities covered by this regulation:

Barceloneta, Puerto Rico
Evansville, IN
Humacao, Puerto Rico
Lawrenceville, NJ
Manati, Puerto Rico
Mayaguez, Puerto Rico
New Brunswick, NJ
Syracuse, NY
Zeeland, MI

The information is also available from each facility page.

Verification

Since 1997, Bristol-Myers Squibb has engaged two types of review and verification of our EHS performance. First, we contract with a third party to assess the elements and performance of our corporate EHS evaluation process. This assessment provides an independent opinion about the program’s ability to provide competent, reliable, and objective information about Bristol-Myers Squibb’s compliance programs and EHS performance.

Second, our systems for collecting and reporting data from our facilities worldwide undergo a third-party assessment. This assessment provides an independent, third-party review of the EHS data collection systems. The assessment includes document reviews, use of software applications for data collection, and interviews with key personnel with responsibilities related to data collection and utilization.

Independent statements regarding these reviews are included in this website.

Normalizing Data

Normalization of data is an important technique for tracking environmental performance and measuring eco-efficiency. Tying releases, recycling, and resource consumption to a unit of production helps clarify whether positive trends are the result of pollution prevention activities or simply the effect of decreased manufacturing activity.

Normalizing data to production is not currently feasible for a company like Bristol-Myers Squibb because we produce such diverse products — from anti-cancer drugs to ostomy products to infant formula. However, we encourage individual facilities to move toward this approach. We continue to examine other options for normalizing data on a companywide basis.

In the interim, we have normalized data to worldwide sales and report in U.S. dollars. We acknowledge the shortcomings of this approach. Several factors, including inflation, currency fluctuations, and licensing agreements, can affect sales without impacting production levels or environmental operating results. Nonetheless, sales dollars apply to all our operations, at all of our divisions worldwide and represent the best normalizing measure currently available to us. We have revised the sales figures used in the normalized data to reflect financial restatements for 2005.

We provide both absolute and normalized data on this website.

Acquisitions and Divestitures

We include facilities in our data collection and reporting systems for full calendar years only. Newly opened facilities are included in the first full calendar year of operation. New acquisitions are included within two full calendar years. If a facility is divested or closed, data from the facility are included only through the last full calendar year it was part of Bristol-Myers Squibb.

Last updated October 22, 2007 . Italicized product names are registered trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Copyright © 1998-2006 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notices.